Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 11174267
Spiroindolinones and therapeutic uses thereof
granted -
US 11174320
HER3 specific monoclonal antibodies for diagnostic and therapeutic use
granted -
US 11173227
Wound dressings and applications thereof
granted -
US 11174495
Reporter system for detecting and targeting activated cells
granted -
US 11174291
Silstatin compounds
granted -
US 11173318
Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for therapeutic use
granted -
US 11173129
Nanowire-coated microdevice and method of making and using the same
granted -
US 11173164
Compositions comprising triterpenoids
granted -
US 11173145
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
granted -
US 11173235
Nitrite eluting devices and methods of use thereof
granted -
US 11173207
Adjuvant compositions
granted -
US 11166949
NURR1 activation in the treatment of metabolic disorders and as an exercise mimetic
granted -
US 11166957
Antiviral prodrugs and nanoformulations thereof
granted -
US 11168082
Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors
granted -
US 11166962
Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
granted -
US 11168071
Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
granted -
US 11168142
Administration of kynurenine depleting enzymes for tumor therapy
granted -
US 11168325
Methods for treatment of polycystic kidney disease
granted -
US 11169142
Viscoelastic analysis in patients with disease associated with cardiovascular system
granted -
US 11168148
Antibodies to oxidation-specific epitopes
granted -
US 11162096
Methods for modulating expression of C9ORF72 antisense transcript
granted -
US 11162079
Blood type O Rh-hypo-immunogenic pluripotent cells
granted -
US 11162063
Methods and apparatus for conditioning cell populations for cell therapies
granted -
US 11161875
Inhibition of pulmonary fibrosis with nutlin-3a and peptides
granted -
US 11160833
Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
granted -
US 11162945
Methods and compositions for detecting single T cell receptor affinity and sequence
granted -
US 11161908
BAFF-R targeted chimeric antigen receptor-modified t-cells and uses thereof
granted -
US 11160908
Intraocular drug delivery and filter device and methods of using same
granted -
US 11154573
Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
granted -
US 11154606
Vaccine for prevention of necrotic enteritis in poultry
granted -
US 11154639
Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
granted -
US 11154556
Methods of treating solid tumors with CCR2 antagonists
granted -
US 11155804
Recombinant polypeptides comprising selenocysteine and method for producing the same
granted -
US 11155599
Adenoviruses expressing heterologous tumor-associated antigens
granted -
US 11154636
Antimicrobial biopolymer compositions, methods of synthesis, and applications of use
granted -
US 11154572
Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
granted -
US 11154557
Antiviral prodrugs and nanoformulations thereof
granted -
US 11155821
Compositions and methods for tagging ribonucleic acids
granted -
US 11147888
Methods and systems for detecting psychotic disorders associated with serotonin 2A receptor deficiencies
granted -
US 11147746
Hydrophobic dental surfaces
granted -
US 11147795
Neuroprotective compounds and methods of use
granted -
US 11150237
Patient-specific biomarkers of Escherichia coli invasion in inflammatory bowel disease
granted -
US 11147946
Venous access catheters and methods for portal venous system catheterization
granted -
US 11148998
Dimethyl-nonatetraenyl-trimethyl-cyclohexyl compounds and uses thereof
granted -
US 11149025
Anti-cancer compounds
granted -
US 11147885
ASH1L inhibitors and methods of treatment therewith
granted -
US 11142764
Antisense antibacterial compounds and methods
granted -
US 11142505
Compositions for APP-selective BACE inhibition and uses therefor
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory